This post was originally published on this site TG Therapeutics’ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising response rates in patients with relapsed or refractory follicular lymphoma, according to new data from a Phase 2b clinical trial. The UNITY-NHL trial (NCT02793583) included 118 follicular lymphoma patients previously treated with at least…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including financial incentives for therapy development and commercialization, should it be approved. It also provides U.S. market exclusivity for…
MDNA55 Increases Survival in Glioblastoma, Notably in Patients With High ILR4 Levels, Early Trial Data Show
This post was originally published on this site The investigational therapy MDNA55 increases survival in people with recurrent glioblastoma, a type of brain cancer — especially in those who produce high levels of ILR4, a marker of aggressive disease, updated results of a clinical trial show. Fahar Merchant, president and CEO of Medicenna Therapeutics, MDNA55’s…
Most Breast Cancers Found by Hand, MammaCare Researchers Say
This post was originally published on this site Decades after establishing the recognized standard for performing and teaching clinical and personal breast exams, the MammaCare Foundation wants women and others to be aware that most breast cancers are found by hand. MammaCare’s goal is to train people what to feel for to identify suspicious breast…
Use of Assisted Reproduction Techniques Linked to Increased Prostate Cancer Risk, Study Suggests
This post was originally published on this site Men who father children through assisted reproduction techniques, either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), may be at a higher risk of developing prostate cancer, a study shows. Early screening for prostate cancer may also be beneficial for infertile men, according to the study,…
First Patient Enrolled in Trial Testing Defitelio to Prevent Neurotoxicity in DLBCL Patients Receiving CAR T-cell Therapy
This post was originally published on this site Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are receiving chimeric antigen receptor (CAR) T-cell therapy. The multicenter open-label trial…
$1.8M NIH Award to Support Work into Robotic System Able to Better Detect Prostate Cancer
This post was originally published on this site Haichong Zhang, an assistant professor at Worcester Polytechnic Institute, has been given a Director’s Early Independence Award from the National Institutes of Health (NIH) to support his work in designing a robotic system to better detect and monitor prostate cancer. Currently, prostate cancer is diagnosed via a blood…
Syros’ SY-5609 Shows Promising Activity in OC Models, Supports Planned Phase 1 Trial, Results Show
This post was originally published on this site Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings support the initiation of a Phase 1 trial testing the compound early next year, investigators said. Researchers…
Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows
This post was originally published on this site U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio (selinexor) as a fifth-line combination therapy, according to a survey conducted by market research firm Spherix Global Insights. The…
Opdivo-Yervoy Plus Shorter Chemotherapy Course Extends Survival of Patients with Advanced Lung Cancer, Early Trial Data Show
This post was originally published on this site First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell lung cancer (NSCLC), compared to standard chemotherapy alone, early Phase 3 trial results show. The CheckMate-9LA trial (NCT03215706)…
First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer
This post was originally published on this site A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company announced. The trial — called HER2CLIMB-02 (NCT03975647) — is enrolling up to 460 adult patients with metastatic…
Veru Completes Enrollment for Zuclomiphene Citrate Trial for ADT-Induced Hot Flashes in PC
This post was originally published on this site Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the use of zuclomiphene citrate (VERU-944) for the treatment of hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are experienced by about 80% of men on androgen deprivation therapy (ADT). ADT…